业务
货币单位:美元
2025/Q3
名称营收比例
Development and commercialization of icosapent ethyl (VASCEPA)4,967万100.00%
地区
货币单位:美元
2024/FY
名称营收比例
US product revenue, net1.67亿72.92%
Rest of World (RoW) product revenue, net2,422.5万10.60%
许可和特许权使用费收入2,402.4万10.51%
Europe product revenue, net1,366.4万5.98%